This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Aug;35(8):e54-5.

doi: 10.1097/IAE.0000000000000682.

Reply: To PMID 24999721

James A Eadie¹, Michael S Ip

Affiliations

PMID: 26166802
DOI: 10.1097/IAE.0000000000000682

Comment

Reply: To PMID 24999721

James A Eadie et al. Retina. 2015 Aug.

. 2015 Aug;35(8):e54-5.

doi: 10.1097/IAE.0000000000000682.

Authors

James A Eadie¹, Michael S Ip

Affiliation

¹ Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin.

PMID: 26166802
DOI: 10.1097/IAE.0000000000000682

No abstract available

PubMed Disclaimer

Comment on

Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
Eadie JA, Ip MS, Kulkarni AD. Eadie JA, et al. Retina. 2014 Dec;34(12):2439-43. doi: 10.1097/IAE.0000000000000238. Retina. 2014. PMID: 24999721
Correspondence.
Bindra CS Sr, Sen A, Mitra A, Bhushan B. Bindra CS Sr, et al. Retina. 2015 Aug;35(8):e54. doi: 10.1097/IAE.0000000000000681. Retina. 2015. PMID: 26166801 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer